Clinical Trials Browser

INDUSTRY × Multiple Myeloma × ruxolitinib × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT06225310 2025-01-16

KPT-IST-391

Phase 1 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT06209606 2024-12-17

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Phase EARLY_PHASE1 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT03110822 2023-11-01

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Phase 1 Recruiting

134 enrolled

Plasma cell

Multiple Myeloma

NCT02587598 2021-12-08

Study of INCB053914 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

97 enrolled 40 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT00639002 2018-02-13

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Phase 2 Completed

13 enrolled 7 charts

Plasma cell

Multiple Myeloma

Clinical Trials

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

KPT-IST-391

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Study of INCB053914 in Subjects With Advanced Malignancies

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma